Vivo Capital’s Terns Pharmaceuticals TERN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1,334,418
| Closed | -$70.4M | – | 51 |
|
|
2026
Q1 | $70.4M | Sell |
1,334,418
-4,012,510
| -75% | -$165M | 5.85% | 3 |
|
|
2025
Q4 | $216M | Sell |
5,346,928
-1,548,818
| -22% | -$35.8M | 13.96% | 1 |
|
|
2025
Q3 | $51.8M | Hold |
6,895,746
| – | – | 4.17% | 4 |
|
|
2025
Q2 | $25.7M | Hold |
6,895,746
| – | – | 2.63% | 7 |
|
|
2025
Q1 | $19M | Hold |
6,895,746
| – | – | 2.52% | 6 |
|
|
2024
Q4 | $38.2M | Hold |
6,895,746
| – | – | 4.28% | 4 |
|
|
2024
Q3 | $57.5M | Buy |
6,895,746
+712,754
| +12% | +$5.86M | 4.76% | 6 |
|
|
2024
Q2 | $42.1M | Sell |
6,182,992
-475,000
| -7% | -$2.88M | 3.89% | 8 |
|
|
2024
Q1 | $43.7M | Hold |
6,657,992
| – | – | 3.43% | 9 |
|
|
2023
Q4 | $43.2M | Hold |
6,657,992
| – | – | 3.54% | 8 |
|
|
2023
Q3 | $33.5M | Hold |
6,657,992
| – | – | 3.67% | 9 |
|
|
2023
Q2 | $58.3M | Hold |
6,657,992
| – | – | 4.02% | 5 |
|
|
2023
Q1 | $78.8M | Hold |
6,657,992
| – | – | 5.47% | 5 |
|
|
2022
Q4 | $67.8M | Buy |
6,657,992
+758,620
| +13% | +$5.05M | 7.8% | 2 |
|
|
2022
Q3 | $34.7M | Buy |
5,899,372
+3,224,239
| +121% | +$12M | 3.84% | 9 |
|
|
2022
Q2 | $6.63M | Hold |
2,675,133
| – | – | 0.67% | 33 |
|
|
2022
Q1 | $7.95M | Hold |
2,675,133
| – | – | 0.55% | 34 |
|
|
2021
Q4 | $18.9M | Hold |
2,675,133
| – | – | 1.14% | 22 |
|
|
2021
Q3 | $27.9M | Hold |
2,675,133
| – | – | 1.25% | 20 |
|
|
2021
Q2 | $32.8M | Hold |
2,675,133
| – | – | 1.42% | 19 |
|
|
2021
Q1 | $58.9M | Buy |
+2,675,133
| New | +$58.6M | 2.07% | 13 |
|
Other funds holding TERN
Vivo Capital's TERN Position: Q2 2026 in Review
Vivo Capital sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 1,334,418 shares — an estimated $70.4M sold.
Vivo Capital first reported a position in TERN in Q1 2021 and held it in 21 quarters. The position peaked at $216M in Q4 2025. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.
- Vivo Capital reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Vivo Capital sold 1,334,418 Terns Pharmaceuticals shares in Q2 2026, an estimated $70.4M.
- Vivo Capital first reported a position in Terns Pharmaceuticals in Q1 2021 and held it in 21 quarters.
- Vivo Capital's Terns Pharmaceuticals position peaked at $216M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.
Based on Vivo Capital's 13F filing for Q2 2026, filed 14 Aug 2026.